JGC
RPRX icon

J. Goldman & Co’s Royalty Pharma RPRX Stock Holding History

J. Goldman & Co’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-27,200
Closed -$847K – 613
2025
Q1 		$847K Buy
+27,200
New +$862K 0.02% 374

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CIA
Caledonia Investments (Australia) Sydney NSW, Australia $3.44B AUM 20.03% 1-Year Est. Return

J. Goldman & Co's RPRX Position: Q2 2024 in Review

J. Goldman & Co sold out of Royalty Pharma (RPRX) in Q2 2024, closing a stake of 265,334 shares — an estimated $8.06M sold.

J. Goldman & Co first reported a position in RPRX in Q2 2022 and held it in 2 quarters. The position peaked at $8.06M in Q1 2024. 378 funds tracked by Wall St. Rank hold RPRX as of Q2 2024.

  • J. Goldman & Co reported no remaining Royalty Pharma position as of Q2 2024 after selling out during the quarter.
  • J. Goldman & Co sold 265,334 Royalty Pharma shares in Q2 2024, an estimated $8.06M.
  • J. Goldman & Co first reported a position in Royalty Pharma in Q2 2022 and held it in 2 quarters.
  • J. Goldman & Co's Royalty Pharma position peaked at $8.06M in Q1 2024.
  • 378 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2024.

Based on J. Goldman & Co's 13F filing for Q2 2024, filed 14 Aug 2024.